Active Filters

  • (-) PSI Authors = Behe, Martin
  • (-) Keywords ≠ L1CAM
Search Results 1 - 20 of 69

Pages

  • RSS Feed
Select Page
Matrix metalloproteinase-responsive delivery of PEGylated fibroblast growth factor 2
Gutmann, M., Reinhardt, D., Seidensticker, C., Raschig, M., Hahn, L., Moscaroli, A., … Lühmann, T. (2024). Matrix metalloproteinase-responsive delivery of PEGylated fibroblast growth factor 2. ACS Biomaterials Science & Engineering, 10(1), 156-165. https://doi.org/10.1021/acsbiomaterials.3c01511
Relaxed fibronectin: a potential novel target for imaging endometriotic lesions
Trachsel, B., Imobersteg, S., Valpreda, G., Singer, G., Grabherr, R., Ormos, M., … Béhé, M. (2024). Relaxed fibronectin: a potential novel target for imaging endometriotic lesions. EJNMMI Research, 14(1), 17 (11 pp.). https://doi.org/10.1186/s13550-024-01070-0
Towards the magic radioactive bullet: improving targeted radionuclide therapy by reducing the renal retention of radioligands
de Roode, K. E., Joosten, L., & Behe, M. (2024). Towards the magic radioactive bullet: improving targeted radionuclide therapy by reducing the renal retention of radioligands. Pharmaceuticals, 17(2), 256 (31 pp.). https://doi.org/10.3390/ph17020256
Targeting mTORC1 activity to improve efficacy of radioligand therapy in cancer
Grzmil, M., Wiesmann, F., Schibli, R., & Behe, M. (2023). Targeting mTORC1 activity to improve efficacy of radioligand therapy in cancer. Cancers, 15(1), 17 (12 pp.). https://doi.org/10.3390/cancers15010017
Highlight selection of radiochemistry and radiopharmacy developments by editorial board
Kiss, O. C., Scott, P. J. H., Behe, M., Penuelas, I., Passchier, J., Rey, A., … Alves, F. (2023). Highlight selection of radiochemistry and radiopharmacy developments by editorial board. EJNMMI Radiopharmacy and Chemistry, 8(1), 6 (18 pp.). https://doi.org/10.1186/s41181-023-00192-5
Detecting radio- and chemoresistant cells in 3D cancer co-cultures using chromatin biomarkers
Pekeč, T., Venkatachalapathy, S., Shim, A. R., Paysan, D., Grzmil, M., Schibli, R., … Shivashankar, G. V. (2023). Detecting radio- and chemoresistant cells in 3D cancer co-cultures using chromatin biomarkers. Scientific Reports, 13(1), 20662 (14 pp.). https://doi.org/10.1038/s41598-023-47287-2
Signaling network response to <em>α</em>-particle–targeted therapy with the <sup>225</sup>Ac-labeled minigastrin analog <sup>225</sup>Ac-PP-F11N reveals the radiosensitizing potential of histone deacetylase inhibitors
Qin, Y., Imobersteg, S., Frank, S., Blanc, A., Chiorazzo, T., Berger, P., … Grzmil, M. (2023). Signaling network response to α-particle–targeted therapy with the 225Ac-labeled minigastrin analog 225Ac-PP-F11N reveals the radiosensitizing potential of histone deacetylase inhibitors. Journal of Nuclear Medicine, 64(6), 873-879. https://doi.org/10.2967/jnumed.122.264597
Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK
Trachsel, B., Valpreda, G., Lutz, A., Schibli, R., Mu, L., & Béhé, M. (2023). Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK. EJNMMI Radiopharmacy and Chemistry, 8(1), 21 (11 pp.). https://doi.org/10.1186/s41181-023-00206-2
EANM guideline on quality risk management for radiopharmaceuticals
Gillings, N., Hjelstuen, O., Behe, M., Decristoforo, C., Elsinga, P. H., Ferrari, V., … Walte, A. (2022). EANM guideline on quality risk management for radiopharmaceuticals. European Journal of Nuclear Medicine and Molecular Imaging, 49, 3353-3364. https://doi.org/10.1007/s00259-022-05738-4
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)
Grzmil, M., Boersema, P., Sharma, A., Blanc, A., Imobersteg, S., Pruschy, M., … Behe, M. (2022). Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT). Journal of Hematology & Oncology, 15(1), 123 (5 pp.). https://doi.org/10.1186/s13045-022-01343-y
A multispecific anti-CD40 DARPin construct induces tumor-selective CD40 activation and tumor regression
Rigamonti, N., Veitonmäki, N., Domke, C., Barsin, S., Jetzer, S., Abdelmotaleb, O., … Trail, P. A. (2022). A multispecific anti-CD40 DARPin construct induces tumor-selective CD40 activation and tumor regression. Cancer Immunology Research, 10(5), 626-640. https://doi.org/10.1158/2326-6066.CIR-21-0553
Dual MVK cleavable linkers effectively reduce renal retention of <sup>111</sup>In-fibronectin-binding peptides
Valpreda, G., Trachsel, B., Vogel, V., Schibli, R., Mu, L., & Behe, M. (2022). Dual MVK cleavable linkers effectively reduce renal retention of 111In-fibronectin-binding peptides. Bioorganic and Medicinal Chemistry, 73, 117040 (11 pp.). https://doi.org/10.1016/j.bmc.2022.117040
Highlight selection of radiochemistry and radiopharmacy developments by editorial board
Aime, S., Al-Qahtani, M., Behe, M., Bormans, G., Carlucci, G., DaSilva, J. N., … Yang, Z. (2021). Highlight selection of radiochemistry and radiopharmacy developments by editorial board. EJNMMI Radiopharmacy and Chemistry, 6(1), 13 (19 pp.). https://doi.org/10.1186/s41181-021-00128-x
Highlight selection of radiochemistry and radiopharmacy developments by editorial board (January-June 2020)
Al-Qahtani, M., Behe, M., Bormans, G., Carlucci, G., Dasilva, J., Decristoforo, C., … Vugts, D. (2021). Highlight selection of radiochemistry and radiopharmacy developments by editorial board (January-June 2020). EJNMMI Radiopharmacy and Chemistry, 6(1), 5 (13 pp.). https://doi.org/10.1186/s41181-020-00118-5
Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals
Gillings, N., Hjelstuen, O., Ballinger, J., Behe, M., Decristoforo, C., Elsinga, P., … Todde, S. (2021). Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. EJNMMI Radiopharmacy and Chemistry, 6(1), 8 (22 pp.). https://doi.org/10.1186/s41181-021-00123-2
1,5-Disubstituted 1,2,3-triazoles as amide bond isosteres yield novel tumor-targeting minigastrin analogs
Grob, N. M., Schibli, R., Béhé, M., Valverde, I. E., & Mindt, T. L. (2021). 1,5-Disubstituted 1,2,3-triazoles as amide bond isosteres yield novel tumor-targeting minigastrin analogs. ACS Medicinal Chemistry Letters, 12(4), 585-592. https://doi.org/10.1021/acsmedchemlett.0c00636
Improved tumor-targeting with peptidomimetic analogs of minigastrin<sup>177</sup>Lu-PP-F11N
Grob, N. M., Schibli, R., Béhé, M., & Mindt, T. L. (2021). Improved tumor-targeting with peptidomimetic analogs of minigastrin177Lu-PP-F11N. Cancers, 13(11), 2629 (12 pp.). https://doi.org/10.3390/cancers13112629
Therapeutic response of CCKBR-positive tumors to combinatory treatment with everolimus and the radiolabeled minigastrin analogue [<sup>177</sup>Lu]Lu-PP-F11N
Grzmil, M., Imobersteg, S., Blanc, A., Frank, S., Schibli, R., & Béhé, M. P. (2021). Therapeutic response of CCKBR-positive tumors to combinatory treatment with everolimus and the radiolabeled minigastrin analogue [177Lu]Lu-PP-F11N. Pharmaceutics, 13(12), 2156 (8 pp.). https://doi.org/10.3390/pharmaceutics13122156
Exploring the signaling space of a GPCR using bivalent ligands with a rigid oligoproline backbone
Romantini, N., Alam, S., Dobitz, S., Spillmann, M., De Foresta, M., Schibli, R., … Berger, P. (2021). Exploring the signaling space of a GPCR using bivalent ligands with a rigid oligoproline backbone. Proceedings of the National Academy of Sciences of the United States of America PNAS, 118(48), e2108776118 (8 pp.). https://doi.org/10.1073/pnas.2108776118
<em>In vivo</em> imaging of local inflammation: monitoring LPS-induced CD80/CD86 upregulation by PET
Taddio, M. F., Castro Jaramillo, C. A., Runge, P., Blanc, A., Keller, C., Talip, Z., … Krämer, S. D. (2021). In vivo imaging of local inflammation: monitoring LPS-induced CD80/CD86 upregulation by PET. Molecular Imaging and Biology, 23, 196-207. https://doi.org/10.1007/s11307-020-01543-3
 

Pages